Scientific Industries Inc
SCND- Exchange
- OTC
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0000087802
In the last 90 days, Scientific Industries Inc insiders filed 5 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 11:15 AM ET
Revenue flow, FY2026
Where the revenue went in FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2026: $1.22M (24.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Jun 30, 2022 |
| Filing | 10-K | 10-K | 10-K/A | 10-KT | 10-K |
| Reported | – | – | – | – | – |
| Revenue | $5.05M | $10.7M | $11.1M | – | $11.4M |
| Cost of revenue | $3.75M | $5.98M | $6.01M | – | $5.66M |
| Gross profit | $1.30M | $4.73M | $5.10M | – | $5.74M |
| Operating expenses | $9.19M | $11.4M | $14.4M | – | $13.0M |
| Research and development | $2.49M | $2.91M | $3.57M | – | $2.87M |
| Selling, general and administrative | $3.27M | $4.82M | $5.42M | – | $5.82M |
| Operating income | -$7.89M | -$6.64M | -$9.26M | – | -$7.26M |
| Income tax | $4.60K | $0 | $0 | – | -$1.35M |
| Net income | -$1.22M | -$6.45M | -$9.09M | – | -$5.64M |
| EPS, diluted | $-0.11 | $-0.61 | – | – | – |
| Weighted shares, diluted | 11.3M | 10.5M | 10.1M | – | 6.64M |
| Margins and growth | |||||
| Gross margin | 25.8% | 44.2% | 45.9% | – | 50.3% |
| Operating margin | -156.1% | -62.0% | -83.3% | – | -63.7% |
| Net margin | -24.1% | -60.2% | -81.8% | – | -49.5% |
| Revenue growth, year over year | −52.8% | −3.6% | – | – | +16.6% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Jun 30, 2022 |
| Filing | 10-K | 10-K | 10-K/A | 10-KT | 10-K |
| Reported | – | – | – | – | – |
| Cash and equivalents | – | – | – | $1.93M | $2.97M |
| Short-term investments | – | – | – | – | $6.39M |
| Accounts receivable | $865.8K | $1.20M | $1.16M | $1.31M | $1.50M |
| Inventory | $1.40M | $4.09M | $4.88M | $4.86M | $4.70M |
| Total current assets | $10.4M | $8.29M | $12.3M | $13.0M | $16.3M |
| Property, plant and equipment | $690.9K | $885.0K | $1.08M | $1.16M | $1.01M |
| Goodwill | $115.3K | $115.3K | $115.3K | $115.3K | $4.40M |
| Intangible assets | $103.5K | $752.3K | – | $1.76M | $2.08M |
| Total assets | $12.6M | $11.6M | $16.7M | $18.1M | $29.0M |
| Accounts payable | $449.1K | $586.1K | $711.7K | $887.3K | $1.11M |
| Total current liabilities | $1.35M | $1.75M | $1.84M | $2.12M | $2.23M |
| Total liabilities | $1.94M | $2.44M | $2.85M | $3.28M | $3.47M |
| Shareholders' equity | $10.7M | $9.12M | $13.9M | $14.8M | $25.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Jun 30, 2022 |
| Filing | 10-K | 10-K | 10-K/A | 10-KT | 10-K |
| Reported | – | – | – | – | – |
| Operating cash flow | – | -$3.68M | -$6.16M | – | -$5.51M |
| Capital expenditures | $63.2K | $98.9K | $131.7K | – | $757.6K |
| Free cash flow | – | -$3.78M | -$6.29M | – | -$6.27M |
| Depreciation and amortization | $610.0K | $750.7K | $754.0K | – | $688.2K |
| Stock-based compensation | $520.7K | $1.17M | $2.24M | – | $2.35M |
| Investing cash flow | $3.83M | $2.87M | -$735.1K | – | -$3.75M |
| Financing cash flow | $1.95M | $645.7K | $5.75M | – | $2.63M |
| Net change in cash | $328.4K | -$208.2K | -$1.13M | – | -$6.70M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 10.3% | 10.9% | 20.2% | – | 20.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 13, 2026 | 11.9M | +3.2% | SEC |
| May 13, 2026 | 11.9M | +3.2% | SEC |
| Mar 27, 2026 | 11.9M | +13.6% | SEC |
| Nov 19, 2025 | 11.9M | +13.6% | SEC |
| Aug 19, 2025 | 11.6M | +10.0% | SEC |
| May 13, 2025 | 11.6M | +10.0% | SEC |
| Mar 29, 2025 | 10.5M | 0.0% | SEC |
| Nov 13, 2024 | 10.5M | +50.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.